Menu
Content/Inhalt
Home
|
Careers
|
Contact us
Search
Welcome
History
Social responsibility
Our companies
Debiopharm Group
Debiopharm S.A.
Debio R.P. S.A.
Debioclinic S.A.
Debiovision Inc.
Debioinnovation S.A.
Business Model
Strengths
Development capabilites
Preclinical
Clinical
Manufacturing
Regulatory
Innovative drug delivery and formulation
Partnering
Licensing-in
Licensing-out
Partners
Pipeline
Commercial Products
Eloxatin®
Decapeptyl®
News & Events
Press Releases
Awards
Publications
Conferences
News
20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions
Home
News & Events
Publications
Debio 025
Evaluation of a cyclophilin inhibitor in Hepatitis C virus-infected chimeric mice in vivo
Inoue K, Umehara T, Ruegg UT, Yasui F, Watanabe T, Yasuda H, Dumont JM, Scalfaro P, Yoshiba M, Kohara M.
Hepatology Apr 2007;45:921-928
